Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Pigmentation · Melanocortin

Melanotan I (Afamelanotide)

Selective MC1R agonist FDA-approved for erythropoietic protoporphyria.

FDA-Approved

Plain-Language Label Highlights

Brand names: Scenesse (afamelanotide)

What it's approved for

Increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP).

A small implant placed under the skin every two months that boosts protective skin pigment so people with EPP can tolerate light.

Common side effects
  • Implant-site reactions
  • Headache
  • Nausea
  • Skin darkening
  • New or darkening moles
Serious risks to know
  • Skin cancer risk — annual full-skin exams required
  • Hyperpigmentation
  • Allergic reactions
Who should avoid or use with extra caution
  • Hepatic impairment
  • History of melanoma or current suspicious skin lesions
  • Pregnancy/lactation (limited data)

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

A selective melanocortin-1 receptor (MC1R) agonist that stimulates eumelanin production in melanocytes. FDA-approved (Scenesse) as an implant for erythropoietic protoporphyria, a rare light-sensitive disorder.

Research Areas

Erythropoietic protoporphyria (FDA-approved)
UV-independent tanning (research)
Photoprotection in photosensitivity disorders

Common Research Protocols

Implant clinical use

Subcutaneous implant every 2 months in approved indication.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]New England Journal of Medicine·2015

Afamelanotide for erythropoietic protoporphyria

Phase 3 trials showed significant pain reduction and sun tolerance.

Important Considerations

  • FDA-approved for EPP via implant formulation only.
  • Not approved for cosmetic tanning.
  • Monitoring for new/changing moles recommended.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Melanotan I (Afamelanotide)

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.